| Schizophrenia

Cobenfy vs Abilify Asimtufii

Side-by-side clinical, coverage, and cost comparison for schizophrenia.

Deep comparison between: Cobenfy vs Abilify Asimtufii with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsAbilify Asimtufii has a higher rate of injection site reactions vs Cobenfy based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Abilify Asimtufii but not Cobenfy, including UnitedHealthcare

Category

Cobenfy

Abilify Asimtufii

At A Glance

RouteOral

FrequencyTwice daily

ClassMuscarinic agonist/antagonist combination

RouteIM injection

FrequencyEvery 2 months

ClassAtypical antipsychotic

Indications

Schizophrenia

Schizophrenia
Bipolar I disorder

Dosing

Schizophrenia Starting dose 50 mg/20 mg orally twice daily for at least 2 days, then 100 mg/20 mg twice daily for at least 5 days; may increase to 125 mg/30 mg twice daily based on tolerability and response (maximum dose); take at least 1 hour before or 2 hours after a meal; do not open capsules. Geriatric patients: start at 50 mg/20 mg twice daily, maximum 100 mg/20 mg twice daily.

Schizophrenia, Bipolar I disorder 960 mg IM gluteal injection once every 2 months (56 days); dose may be reduced to 720 mg if adverse reactions occur; CYP2D6 poor metabolizers: 720 mg once every 2 months.

Contraindications

Urinary retention
Moderate (Child-Pugh Class B) or severe (Child-Pugh Class C) hepatic impairment
Gastric retention
History of hypersensitivity to COBENFY or trospium chloride
Untreated narrow-angle glaucoma

Known hypersensitivity to aripiprazole or any excipient

Drug Interactions

712View drug interactions

1324View drug interactions

Adverse Reactions

Most common (>=5%) Nausea, dyspepsia, constipation, vomiting, hypertension, abdominal pain, diarrhea, tachycardia, dizziness, gastroesophageal reflux disease

Serious Urinary retention, liver enzyme elevations, increases in heart rate, angioedema

Postmarketing Chest pain, hypertensive crisis, palpitations, supraventricular tachycardia, syncope, gastritis, rash, rhabdomyolysis, confusion, delirium, hallucinations, somnolence, vision abnormal, angioedema, anaphylactic reaction, Stevens-Johnson syndrome (reported with trospium chloride component)

Most common (>=5%) Increased weight, akathisia, injection site pain, sedation

Serious Neuroleptic malignant syndrome, tardive dyskinesia, metabolic changes, orthostatic hypotension, leukopenia/neutropenia/agranulocytosis, seizures, dysphagia

Postmarketing Anaphylactic reaction, angioedema, DRESS, blood glucose fluctuation, pathological gambling, fecal incontinence, hiccups

Pharmacology

Xanomeline is a muscarinic agonist with preferential activity at M1 and M4 receptors in the central nervous system, where its efficacy in schizophrenia is thought to arise; trospium chloride is a peripheral muscarinic antagonist included to reduce cholinergic adverse effects.

Aripiprazole is an atypical antipsychotic whose efficacy may be mediated through partial agonist activity at dopamine D2 and serotonin 5-HT1A receptors and antagonist activity at serotonin 5-HT2A receptors; the active metabolite dehydro-aripiprazole also has affinity for D2 receptors.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Cobenfy